Aimmune Therapeutics Inc., of Brisbane, Calif., said in the ongoing phase III PALISADE trial of AR-101, an investigational biologic oral immunotherapy for desensitization of patients with peanut allergy, more than 97 percent of patients currently on study have completed up-dosing.